Given the growing utilization of SGLT2 inhibitors in chronic disease management and potential safety concerns, this study aims to conduct a systematic review and meta-analysis to assess their efficacy in improving cardiovascular and renal outcomes beyond glycemic control in patients with T2DM, HF, and CKD, as well as to evaluate the safety profile of these medications. This evidence concerns the gene SLC5A2 and hydrops fetalis.